Diamyd Medical announces final outcome of the exercise of series TO 3 warrants
Diamyd Medical AB (publ) (“Diamyd Medical” or the “Company“) issued a total of 9,165,682 series TO 3 warrants in 2023 as part of a rights issue of units. During the exercise period, which ran from September 2, 2024, to September 30, 2024, a total of 4,365,200 shares have been subscribed for […]
Cell Impact announces outcome in the exercise of warrants of series 2023/2024 TO2
Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) (“Cell Impact” or the “Company”) today announces the outcome of exercise of warrants of series 2023/2024 TO2, which were issued in connection with the Company’s rights issue of units in December 2023. In total, 104,821,096 warrants of series 2023/2024 TO2 were […]